Category: Biotech
-
Nemaura Medical to Launch their non-invasive continuous glucose monitor in the US market under the Wellness Category
Given some recent news, we think investors should take the time to research Nemaura Medical Inc. (NASDAQ: NMRD)
-
Nemaura To Prepare for Launch of sugarBEAT CGM In the U.S. Following FDA Feedback
Loughborough, England, March [18], 2020 — Nemaura Medical Inc (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and…
-
NanoViricides to Produce Broad Spectrum Antiviral Clinical Trial Candidates for COVID-19
The COVID-19 coronavirus is spreading rapidly across the globe despite persistent efforts from Governments to contain its spread.
-
Avivagen’s OxC-beta™ Livestock product May Prevent Future Outbreaks Like The Wuhan Coronavirus
The emerging crisis of the Wuhan coronavirus in China has global implications with over 2,126 deaths worldwide and over 75,700 reported cases, that are increasing with each passing day. The virus has shaken financial markets across all over the world and has adversely affected a number of sectors such as travel and tourism, greatly impacting…
-
Biotech Stocks To The Rescue: The Race to Stop The Wuhan Virus
The Wuhan coronavirus is a brand new respiratory virus that has emerged in China in a metropolis by the identical title. With the outbreak having started in December via the seafood and meat market in Wuhan, central China, the virus has already affected thousands of of individuals and has been attributed to some deaths. The…
-
NanoViricides: Grab This Biopharma Player While Inexpensive
Investment timing is among the most important ideas associated to the world of stock market investing. While its software is essential for investments throughout any and each sector, one specific business the place it’s most related is the biotech business. Often, we see biotech firms with minimal revenues which can be on the verge of…
-
NanoViricides: A Unicorn For Biotech Investors
The OTC markets are filled with zero-revenue biotech companies looking for research funding through issuance of equity but, it is very difficult for investors to evaluate the future potential of most of these players given the complexity of their research, the uncertainty associated with product launches and revenues, and the fact that these companies have…
-
Will Sales Growth Save Cronos Group Inc. (NASDAQ: CRON) From selling Pressure?
[ad_1] Will Sales Growth Save Cronos Group Inc. (NASDAQ: CRON) From selling Pressure? Cronos Group Inc. (NASDAQ: CRON) stays below strain even on reporting a 274% year-over-year enhance in revenues within the latest quarter. The stock has been below strain since touching file highs of $11.90 early within the yr. The stock’s sentiments on the…